Results 201 to 210 of about 16,748,637 (363)

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Clinical Importance of Phosphodiesterase 3 Inhibitors on Outcomes in Patients With Cardiogenic Shock　- A Systematic Review. [PDF]

Circ Rep
Yamamoto M, Hosoya Y, Hanada H, Osawa T, Arai M, Sakamoto K, Okazaki Y, Katasako-Yabumoto A, Ishizu T, Kondo T, Kirigaya J, Nakayama N, Yamamoto T, Hashiba K, Nakashima T, Tsujita K, Noguchi T, Tsujimoto Y, Kikuchi M, Tahara Y, Nonogi H, Matoba T, Japan Resuscitation Council (JRC) Cardiogenic Shock (CS) Task Force and the Guideline Editorial Committee on behalf of the Japanese Circulation Society (JCS) Emergency and Critical Care Committee.   +22 more
europepmc   +1 more source

Plasma Membrane Cyclic Adenosine 3′:5′-Monophosphate Phosphodiesterase of Cultured Cells and Its Modification after Trypsin Treatment of Intact Cells

, 1973
Tom R. Russell, Ira Pastan
openalex   +1 more source

Cytokine Milieu Relevant to Atopic Dermatitis Enhances Epidermal Trypsin‐Like Serine Protease Activity, Which Is Pharmacologically Suppressed in Human Keratinocytes

The Journal of Dermatology, EarlyView.
Shiori Onishi, Yohei Yasutomi, Onon Tsedendorj, Shin Morizane   +3 more
wiley   +1 more source

New biosensors and transgenic mice for multiplex cGMP imaging

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a versatile second messenger that is important for human (patho‐)physiology and pharmacotherapy. Live‐cell imaging of cGMP with biosensors allows to elucidate its spatiotemporal dynamics in real time under close‐to‐native conditions. However, to monitor two separate cGMP pools or cGMP/cAMP
Markus Wolters, Martin Thunemann, Barbara Birk, Susanne Feil, Viacheslav O. Nikolaev, Moritz Lehners, Robert Feil   +6 more
wiley   +1 more source

PDE4D and PDE3B orchestrate distinct cAMP microdomains in 3T3‐L1 adipocytes

British Journal of Pharmacology, EarlyView.
Basal conditions: •Ins/PDE3B lowers cytoplasmic cAMP (cyt‐cAMP) without affecting plasma membrane cAMP (pm‐cAMP). •Insulin decreases lipid droplet cAMP (LD‐cAMP) independent of PDE3B. •FGF1/PDE4D modestly reduces both cyt‐ and pm‐cAMP, while PDE4D alone can modulate LD‐cAMP. ISO stimulation: •Ins/PDE3B has minimal impact on cyt‐cAMP.
Johannes Krier, David Spähn, David Arturo Juarez Lopez, Judith L. Nono, Judith Seigner, Lisa Jacob, Siegfried Ussar, Robert Lukowski, Andreas L. Birkenfeld, Gencer Sancar   +9 more
wiley   +1 more source

Sphingomyelin phosphodiesterase 3 as a novel host factor inhibiting hepatitis B virus transcription. [PDF]

Virol Sin
Li C, Zhou M, Zhao K, Liu W, Zhu C, Cheng X, Xia Y.   +6 more
europepmc   +1 more source

Notes on Three Palustrine Natural Community Types in the Arkansas Ozarks [PDF]

, 1985
Orzell, Steve L., Pell, William F., Tucker, Gary E.   +2 more
core   +2 more sources

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Role of phosphodiesterase-3 inhibitor in cardiorespiratory fitness and functional class of patients with pulmonary hypertension: A randomized, double-blind, placebo-controlled trial. [PDF]

Narra J
Sofia SN, Bahrudin U, Uddin I, Sobirin MA, Setiawati E, Hardaningsih G, Tjandra KC, Limijadi EK.   +7 more
europepmc   +1 more source